Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 13, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The primary material change reported is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on September 9, 2005. The number of Ordinary Share ADRs held by the fund increased from 18,360,149 to 18,415,731. This transaction occurred at an average price of $50.07 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that the Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same capacity as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the exact number of ADRs held by the US Retirement Savings Plan (18,415,731) as of September 9, 2005.
- Confirm the average transaction price of $50.07 for the reported movement.
- Note that the potential interest of Directors Dr. J P Garnier and Dr. T Yamada is indirect through the employee fund.
- Understand that this filing does not contain operational or financial performance data for the period.